Rates of Return in Diagnostics IPOs by Market Cap
This article was originally published in Start Up
The rarest IPOs in recent months have been those in diagnostics, with only three completed so far this year. Nonetheless, we wondered how diagnostics companies that received the highest market caps in IPOs over the past two years fared against their smaller-cap counterparts on delivering rates of return to private investors.
You may also be interested in...
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.